Table 11: **Rev** 

HXB2 Location	Auth	nor Location	Sequence		Immunogen	Species(HLA)	References
Rev(9–23)	• One	(9–23 HXB2) e of four peptides the			HIV-1 infection HIV-1+ donors both (	human() CD4+ Th cell proliferation and CTI	[Blazevic1995a]  to autologous targets
Rev(16–35)	Rev	(16–35 LAI)	VRLIKFLYQS GTR	NPPPNPE-	Vaccine	murine(H-2 <sup>d</sup> )	[Hinkula1997]
Vaccii	ne: Vec	tor/type: DNA	Strain: LAI	HIV compo	nent: Nef, Tat, Rev		
		•				IA epidermally rather than with intraghout Nef and Tat, less for Rev	amuscular protein
Rev(25–39)	• One	(25–39 HXB2) e of four peptides the		-	HIV-1 infection HIV-1+ donors both (	human() CD4+ Th cell proliferation and CTI	[Blazevic1995a]  to autologous targets
Rev(31–50)	Rev	(31–50 LAI)	PEGTRQARRI RERQR	NRRRRW-	Vaccine	$murine(H-2^d)$	[Hinkula1997]
Vaccii	ne: Vec	tor/type: DNA	Strain: LAI	HIV compo	nent: Nef, Tat, Rev		
		•				IA epidermally rather than with intragled that the second rate of the	amuscular protein
Rev(33–48)	Rev	(33–48 HXB2)	GTRQARRNR R	RRRWRE-	HIV-1 infection	human()	[Blazevic1995a]
		e of four peptides the object of the object		PBLs from	HIV-1+ donors both (	CD4+ Th cell proliferation and CTI	to autologous targets
Rev(41–56)	• One	(41–56 HXB2) e of four peptides the			HIV-1 infection HIV-1+ donors both (	human() CD4+ Th cell proliferation and CTI	[Blazevic1995a]  to autologous targets
Rev(76–95)	Rev	(76–95 LAI)	PPLERLTLDC SGTQ	NEDCGT-	Vaccine	murine(H-2 <sup>b</sup> )	[Hinkula1997]
Vaccii	ne: Vec	tor/type: DNA	Strain: LAI	HIV compo	nent: Nef, Tat, Rev		
						IA epidermally rather than with intra ghout Nef and Tat, less for Rev	amuscular protein

Rev(96–	-116)	Rev(96–116 LAI)	GVGSPQILVESP GTKE	TVLES- V	accine	$murine(H-2^d)$	[Hinkula1997]					
	Vaccine:	Vector/type: DNA	Strain: LAI HI	V componer	t: Nef, Tat, Rev							
	<ul> <li>Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein</li> <li>Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev</li> </ul>											
Rev()		Rev()		V	accine	murine()	[Chan1998]					
	Vaccine:	Vector/type: DNA	HIV component: Re	ev								
<ul> <li>Rev M10 is a construct that was introduced into mice through a genetic vaccination</li> <li>Rev was used to test for down-regulation of HIV-1 in infected cells as a method for gene therapy – in the course of this Rev-specific IL-2 producing Th cells developed in the mice</li> </ul>												
Rev()		Rev()		V	accine	human()	[Calarota1999a]					
	Vaccine:	Vector/type: DNA	HIV component: No	ef, Rev Tat								
	•	generated The nef DNA immun Highly active antiretr	ization induced the hi	ghest and m	ost consistent CTLp activ t induce new HIV-specific	tat, and novel proliferative a vity, IFN- $\gamma$ production, and c CTL responses but reduce s this is a potentially compl	IL-6 and IgG responses d viral load, while DNA					
Rev()		Rev()		Н	IV-1 infection, Vaccine	human()	[Calarota2001]					
	Vaccine:	Vector/type: DNA	HIV component: No	ef, Rev, Tat	Stimulatory Agents: (	CpG motifs						
	•		induction of Th1 cytokines uses in asymptomatic HIV+									